Correction to "Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir"

ACS Pharmacol Transl Sci. 2021 Apr 29;4(3):1246. doi: 10.1021/acsptsci.1c00106. eCollection 2021 Jun 11.

Authors

Affiliations

¹ Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.
² Institute of Molecular Biology, Academia Sinica, Taipei 115, Taiwan.
³ Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 350, Taiwan.
⁴ Department of Chemistry, National Tsing Hua University, Hsinchu 300, Taiwan.

Abstract

[This corrects the article DOI: 10.1021/acsptsci.1c00022.].

© 2021 American Chemical Society.

Publication types

Published Erratum